CN104001077A - Traditional Chinese medicine composition for treating urinary tract infection and application thereof - Google Patents
Traditional Chinese medicine composition for treating urinary tract infection and application thereof Download PDFInfo
- Publication number
- CN104001077A CN104001077A CN201410243085.6A CN201410243085A CN104001077A CN 104001077 A CN104001077 A CN 104001077A CN 201410243085 A CN201410243085 A CN 201410243085A CN 104001077 A CN104001077 A CN 104001077A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- urinary tract
- tract infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating urinary tract infection and an application thereof. The traditional Chinese medicine composition is prepared from the following medicinal raw materials in parts by weight: 10-15 parts of rhizoma anemarrhenae, 10-15 parts of cortex phellodendri, 10-15 parts of epimedium, 10-15 parts of rhizoma curculiginis, 5-10 parts of prepared daughter root of common monkshood, 15-30 parts of rice kernels and 15-30 parts of dahurian patrinia herb. The traditional Chinese medicine composition has the advantages that the rice kernels have the effect of tonifying spleen and excreting dampness, the dahurian patrinia herb has the effects of clearing heat and removing toxicity, the prepared daughter root of common monkshood has the effects of tonifying fire, helping yang, dispelling cold and removing humidity, the rhizoma curculiginis and the epimedium have the effects of warming and invigorating kidney yang, the cortex phellodendri and the rhizoma anemarrhenae have the effects of discharging fire and concentrating yin, the traditional Chinese medicine composition has an obvious treatment effect on urinary tract infection, is capable of obviously improving the quality of life of patients and effectively reducing the recurrence rate, the long-term effect is obvious, the number of the herbal medicines is small, and the traditional Chinese medicine composition is low in cost and has no toxic or side effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and application thereof for the treatment of urinary tract infection, specifically, is a kind of Chinese patent medicine of preparing taking Chinese herbal medicine as raw material.
Background technology
Urinary tract infection (UTI, claims again urinary tract infection, is called for short urine sense) is common clinical, frequently-occurring disease.Due to factors such as physiological make-ups, the sickness rate of women's urinary tract infection is far away higher than male, and domestic generaI investigation statistics men and women's ratio reaches 1:10, and especially for menopause and postclimacteric middle and aged women, its sickness rate is 16%-43.3%.Be reported in 65 years old abroad or above non-be in hospital in women at least 20% has bacteriuria, the elderly woman repeatedly incidence rate of urinary tract infection is about 33%.Symptomatic urinary tract infection repeatedly, causes these female patient human body and spiritual burden, has had a strong impact on their quality of life.
At present mainly still select responsive antibacterials to carry out regular treatment for the western medical treatment of urinary tract infection, more than 90% urine bacterium can transfer feminine gender to, once but drug withdrawal, recurrence rate is very high.In recent years, although new effective antibiotic is constantly joined treatment, preventive measure is also strengthened day by day, and its sickness rate, relapse rate and case fatality rate do not reduce.So prevent that the recurrence of urine sense from being one of current problem demanding prompt solution.
For the urinary tract infection of repeatedly showing effect, belong to stranguria caused by overstrain in the traditional Chinese medical science, as Zhang Xichun describes: " card of stranguria caused by overstrain, urine can not be born less, wants just multiple after an action of the bowels, usually has a pain ".Its pathogenesis is taking positive QI-insufficiency as this, and damp-heat in the urinary bladder is mark, deficiency in origin and excess in superficiality, deficiency syndrome mingling with excess syndrome.In " General Treatise on the Cause and Symptoms of Diseases all gonorrhea wait ", say: " Zhu Linzhe, therefore damp-heat in the urinary bladder is also by suffering from a deficiency of the kidney ".The treatment of stranguria caused by overstrain is that this, damp-heat in the urinary bladder are target pathogenic characteristic when taking deficiency of kidney-QI into account." medical science main story stranguria with urinary obstruction " said: " the suffer from a deficiency of the kidney utmost point and pouring person, when the kidney invigorating essence and diuresis, can not private diuretic medicine.”。
Chinese periodical " journal of shanghai Chinese medicine ", 01 phase in 2008, the paper of publishing " adds the observation of curative effect of taste ERXIAN TANG combination antibiotic treatment middle and aged women Chronic Urinary Tract Infection ", has observed the clinical efficacy that adds taste ERXIAN TANG combination antibiotic treatment middle and aged women Chronic Urinary Tract Infection.Method: 52 routine middle and aged women Chronic Urinary Tract Infection patients (the unclear type of insufficiency of kidney-YANG, remaining heresy) are divided into two groups, every group of each 26 examples at random.Matched group gives sensitive antibiotic, enough 14d; Catabasis is taken at bed time every night and uses single dose antibiotic 1 time.Treatment group is except selecting sensitive antibiotic, then gives and add taste ERXIAN TANG and (add taste ERXIAN TANG side medicine composition: Rhizoma Curculiginis 10g, Herba Epimedii 10g, Radix Morindae Officinalis 9g, Cortex Phellodendri 15g, Rhizoma Anemarrhenae 15g, Radix Angelicae Sinensis 9g, Herba Taraxaci 15g, Herba Violae 15g.Plus-minus: frequent micturition, the obvious person of symptoms of urgency are with Herba Dianthi, Herba Polygoni Avicularis; The obvious person of weak, Mental fatigue adds Rhizoma Dioscoreae, Fructus Corni; The obvious person of lower abdominal distention pain adds the Radix Linderae, Fructus Foeniculi; Xerostomia, the obvious person of the soreness of waist add Fructus Ligustri Lucidi, Herba Ecliptae; Waist twinge or tongue secretly have ecchymosis, and person adds Semen Persicae, Flos Carthami.）。Two groups equal 2 weeks is 1 course for the treatment of, treats 3 courses for the treatment of.Observe patient treatment front and back short term effect, and follow up a case by regular visits to and within 6 months, observe late result and recurrence.After result treatment, the every clinical symptoms for the treatment of group is improved obvious compared with matched group: relatively not statistically significant (P>0.05) of two groups of short term effects; Treatment group relapse rate is starkly lower than matched group (P<0.05).Conclusion: add taste ERXIAN TANG and can obviously improve the clinical symptoms of middle and aged women Chronic Urinary Tract Infection, reduce relapse rate.
Chinese periodical " Chinese combination of Chinese and Western medicine nephropathy magazine ", the 7th phase in 2011, the paper published " comparative study of two fourth ERXIAN TANG and SANJIN PIAN treatment recidivity urinary tract infection ", includes 80 routine chronic urinary tract infection middle and aged women patients in, meets that Syndrome in TCM belongs to insufficiency of kidney-YANG, remaining heresy is unclear.First give Primary Care, give after sensitive antibiotic treatment 14d alleviation according to Urine culture, inactive antibiotics, include test in, be divided into two groups by randomly assigne, every group of each 40 examples, carry out GP TH, wherein treatment group is taken two fourth ERXIAN TANG (chief component: Herba Epimedii 20g, Rhizoma Curculiginis 15g, Radix Morindae Officinalis 10g, Radix Angelicae Sinensis 10g, Cortex Phellodendri 15g, Rhizoma Anemarrhenae 15g, Herba Taraxaci 15g, Herba Violae 15g), and matched group is taken SANJIN PIAN.Two groups all taking 4 weeks as 1 course for the treatment of, treats altogether 2 courses for the treatment of.Observe patient treatment front and back short term effect and tcm syndrome curative effect, quality of life; Follow up a case by regular visits to 6 months, observe late relapse rate.Result: after the treatment of 8 weeks, treatment group and matched group all have significant difference at recent effective percentage (92.5% vs 72.5%), tcm syndrome effective percentage (95% vs 45%), clinical symptoms integration (5.25 ± 2.42 vs 14.90 ± 4.69), SF-36 scale integration (112.06 ± 8.85 vs 97.36 ± 10.67), and the curative effect for the treatment of group is better than matched group; During following up a case by regular visits to 6 months, treatment group relapse rate (12.5%) is lower than matched group (30%).Conclusion: with SANJIN PIAN comparison, two fourth ERXIAN TANG can obviously be improved Syndrome in TCM and belong to the not middle and aged women recidivity urinary tract infection patient's of clear type clinical symptoms and quality of life of insufficiency of kidney-YANG, remaining heresy, reduce relapse rate, and safety has no side effect.
For further promoting the treatment of urinary tract infection, effectively prevent recurrence, find evident in efficacyly, especially the significant Chinese medicine composition of late result remains very necessary.
Summary of the invention
The object of the invention is for deficiency of the prior art, a kind of Chinese medicine composition for the treatment of urinary tract infection is provided.
One object more of the present invention is that the purposes of above-mentioned Chinese medicine composition is provided.
For achieving the above object, the technical scheme that the present invention takes is:
Treat a Chinese medicine composition for urinary tract infection, it is to be made up of the crude drug of following weight portion: Rhizoma Anemarrhenae 10-15 part, Cortex Phellodendri 10-15 part, Herba Epimedii 10-15 part, Rhizoma Curculiginis 10-15 part, Radix Aconiti Lateralis Preparata 5-10 part, Semen Coicis 15-30 part, Herba Patriniae 15-30 part.
Described Chinese medicine composition is to be made up of the crude drug of following weight portion: Rhizoma Anemarrhenae 12-14 part, Cortex Phellodendri 12-14 part, Herba Epimedii 12-14 part, Rhizoma Curculiginis 12-14 part, Radix Aconiti Lateralis Preparata 7-9 part, Semen Coicis 20-25 part, Herba Patriniae 20-25 part.
Described Chinese medicine composition is to be made up of the crude drug of following weight portion: 13 parts of the Rhizoma Anemarrhenaes, 13 parts of Cortex Phellodendris, 13 parts of Herba Epimedii, 13 parts of Rhizoma Curculiginises, 8 parts of Radix Aconiti Lateralis Preparatas, 22 parts of Semen Coicis, 22 parts of Herba Patriniae.
The medicament of described Chinese medicine composition is decoction, capsule, granule, tablet or mixture.
For realizing above-mentioned second object, the technical scheme that the present invention takes is:
As above the application of arbitrary described Chinese medicine composition in the medicine of preparation treatment urinary tract infection.
As above the application of arbitrary described Chinese medicine composition in the medicine of preparation treatment urinary tract repeated infection.
The invention has the advantages that:
1, Chinese medicine composition of the present invention adopts Semen Coicis spleen invigorating eliminating dampness by diuresis, Herba Patriniae heat-clearing and toxic substances removing, it is supporing yang that Radix Aconiti Lateralis Preparata is mended fire, Rhizoma Curculiginis, Herba Epimedii warming and recuperating the kidney-YANG, the moon is deposited in Cortex Phellodendri, Rhizoma Anemarrhenae pathogenic fire purging, and treatment urinary tract infection effect is remarkable, effective percentage and tcm syndrome curative effect are better than two fourth ERXIAN TANG of the prior art in the recent period, can significantly improve patient's quality of life, especially effectively reduce relapse rate, late result is obvious;
2, flavour of a drug number is few, is convenient to preparation, and abundant raw materials is easy to get, and low price is suitable for promoting;
3, made by pure Chinese medicine, have no side effect, be easy to be accepted by patient.
[detailed description of the invention]
Below detailed description of the invention provided by the invention is elaborated.
the preparation (one) of embodiment 1 Chinese medicine composition of the present invention
13 parts of the Rhizoma Anemarrhenaes, 13 parts of Cortex Phellodendris, 13 parts of Herba Epimedii, 13 parts of Rhizoma Curculiginises, 8 parts of Radix Aconiti Lateralis Preparatas, 22 parts of Semen Coicis, 22 parts of Herba Patriniae, conventional method decocts.
the preparation (two) of embodiment 2 Chinese medicine compositions of the present invention
10 parts of the Rhizoma Anemarrhenaes, 15 parts of Cortex Phellodendris, 10 parts of Herba Epimedii, 15 parts of Rhizoma Curculiginises, 5 parts of Radix Aconiti Lateralis Preparatas, 30 parts of Semen Coicis, 15 parts of Herba Patriniae, conventional method decocts.
the preparation (three) of embodiment 3 Chinese medicine compositions of the present invention
15 parts of the Rhizoma Anemarrhenaes, 10 parts of Cortex Phellodendris, 15 parts of Herba Epimedii, 10 parts of Rhizoma Curculiginises, 10 parts of Radix Aconiti Lateralis Preparatas, 15 parts of Semen Coicis, 30 parts of Herba Patriniae, conventional method decocts.
the preparation (four) of embodiment 4 Chinese medicine compositions of the present invention
10 parts of the Rhizoma Anemarrhenaes, 10 parts of Cortex Phellodendris, 15 parts of Herba Epimedii, 15 parts of Rhizoma Curculiginises, 5 parts of Radix Aconiti Lateralis Preparatas, 15 parts of Semen Coicis, 30 parts of Herba Patriniae, conventional method decocts.
the preparation (five) of embodiment 5 Chinese medicine compositions of the present invention
15 parts of the Rhizoma Anemarrhenaes, 15 parts of Cortex Phellodendris, 10 parts of Herba Epimedii, 10 parts of Rhizoma Curculiginises, 10 parts of Radix Aconiti Lateralis Preparatas, 30 parts of Semen Coicis, 15 parts of Herba Patriniae, conventional method decocts.
the preparation (six) of embodiment 6 Chinese medicine compositions of the present invention
10 parts of the Rhizoma Anemarrhenaes, 10 parts of Cortex Phellodendris, 10 parts of Herba Epimedii, 15 parts of Rhizoma Curculiginises, 10 parts of Radix Aconiti Lateralis Preparatas, 30 parts of Semen Coicis, 15 parts of Herba Patriniae, conventional method decocts.
the preparation (seven) of embodiment 7 Chinese medicine compositions of the present invention
12 parts of the Rhizoma Anemarrhenaes, 14 parts of Cortex Phellodendris, 12 parts of Herba Epimedii, 14 parts of Rhizoma Curculiginises, 7 parts of Radix Aconiti Lateralis Preparatas, 25 parts of Semen Coicis, 20 parts of Herba Patriniae, conventional method decocts.
the preparation (eight) of embodiment 8 Chinese medicine compositions of the present invention
14 parts of the Rhizoma Anemarrhenaes, 12 parts of Cortex Phellodendris, 14 parts of Herba Epimedii, 12 parts of Rhizoma Curculiginises, 9 parts of Radix Aconiti Lateralis Preparatas, 20 parts of Semen Coicis, 25 parts of Herba Patriniae, conventional method decocts.
the preparation (nine) of embodiment 9 Chinese medicine compositions of the present invention
10 parts of the Rhizoma Anemarrhenaes, 14 parts of Cortex Phellodendris, 14 parts of Herba Epimedii, 10 parts of Rhizoma Curculiginises, 10 parts of Radix Aconiti Lateralis Preparatas, 15 parts of Semen Coicis, 15 parts of Herba Patriniae, conventional method decocts.
the preparation (ten) of embodiment 10 Chinese medicine compositions of the present invention
15 parts of the Rhizoma Anemarrhenaes, 12 parts of Cortex Phellodendris, 12 parts of Herba Epimedii, 14 parts of Rhizoma Curculiginises, 5 parts of Radix Aconiti Lateralis Preparatas, 30 parts of Semen Coicis, 30 parts of Herba Patriniae, conventional method decocts.
It should be noted that, it is the manufacture method of Chinese medicine decoction routine that the conventional method described in embodiment 1-10 decocts, and decocts with water into decoction by described crude drug.
the preparation of embodiment 11 Chinese medicine composition tablet/capsules of the present invention
Get the arbitrary described Chinese medicine composition of embodiment 1-10, add 8-12 times of water gaging, decoct 1-3 hour, leach medicine juice.Add again 10 times of water gagings, decoct 1.5-2.5 hour, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add 2.5 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying, pulverizes and granulates, and is pressed into tablet or fills encapsulated dose.
the preparation of embodiment 12 Chinese medicinal composition granules of the present invention
?get the arbitrary described Chinese medicine composition of embodiment 1-10, add 8-10 times of water gaging, decoct 2.5-3.5 hour, leach medicine juice.Add again 10 times of water gagings, decoct 2 hours, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add 2 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, dry, granulate, obtains 20g granule, subpackage 10g/ bag.
the preparation of embodiment 13 Chinese medicine composition mixture of the present invention
Get the arbitrary described Chinese medicine composition of embodiment 1-10, add 8-10 times of water gaging, decoct 3 hours, leach medicine juice.Add again 8 times of water gagings, decoct 2 hours, leach medicine juice, merge secondary decocting liquid, leave standstill, leaching supernatant, concentrated, let cool, add 2 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make mixture.
the clinical trial of embodiment 14 traditional Chinese medicine composition for treating urinary tract infection of the present invention
1. data and method
1.1 case sources
Collect 2007.10 months to 2008.5 months by Yueyang, Shanghai City hospitals of traditional Chinese and western medicine Urology Department outpatient clinic and ward inpatient, enter group according to including the time according to table of random number random assortment, wherein Chinese drug-treated group 40 examples of the present invention, two fourth ERXIAN TANG group 40 examples, SANJIN PIAN group 40 examples.
1.2 select case standard
1.2.1 Western medicine diagnose standard
With reference to the diagnostic criteria of urinary tract infection in " guideline of clinical investigations of new Chinese medicine treatment urinary system infection ".Condition below possessing in making a definite diagnosis urinary tract infection: urinary tract infection occurred in half a year 3 infection above more than 2 times or in 1 year, cultivate clump count >10 in stage of attack through urine
5the acute non-complex urinary tract infection person of/ml.Can diagnosing chronic urinary tract infection, i.e. recidivity urinary tract infection.
1.2.2 tcm diagnosis standard
Insufficiency of kidney-YANG, the unclear type of remaining heresy (" guideline of clinical investigations of new Chinese medicine treatment urinary system infection " formulated with reference to Ministry of Public Health: frequent micturition, urgent micturition, dysurea, dribble of urine, sagging distention in the smaller abdomen, waist dull pain, dizzy weak, edema that face foot is slight, pale tongue, thready and weak pulse or heavy thin.The course of disease is long, outbreak repeatedly, the touching difficulty feature such as heal.
1.2.3 inclusive criteria
Meet the diagnostic criteria of doctor trained in Western medicine Chronic Urinary Tract Infection; Meet Standards of Chinese Medical Syndrome Differentiation; Age is in 45-75 year; Sex: women.
1.2.4 exclusion standard
1. the acute urinary tract infection person of acute pyelonephritis or first attack; 2. imaging examination is found the pathological changes such as urinary tract deformity, calculus, hydrops; 3. urethral syndrome; 4. the chronic renal failure of serum creatinine >=442 μ mol/L; 5. gestation or nursing women; 6. two kinds of control drug of this test are had to allergies or allergic constitution person; 7. the heart, liver, renal function grievous injury or suffer from other serious underlying diseases persons such as diabetes; 8. severe central nervous system disease patient.
1.3 Therapeutic Method
1.3.1 Primary Care
After each group is all given sensitive antibiotic treatment 14 days according to Urine culture and is alleviated, the antibiotics of stopping using.
1.3.2 GP TH
After Primary Care, be divided at random 3 groups.Chinese drug-treated group of the present invention is taken decoction prepared by embodiment 1, decocts to containing crude drug amount 0.30g/mL, and 1 dose of every day, 1 dose is 100mL, and a point morning and evening takes for 2 times; Two fourth ERXIAN TANG groups are taken two fourth ERXIAN TANG, chief component: Herba Epimedii 20g, Rhizoma Curculiginis 15g, Radix Morindae Officinalis 10g, Radix Angelicae Sinensis 10g, Cortex Phellodendri 15g, Rhizoma Anemarrhenae 15g, Herba Taraxaci 15g, Herba Violae 15g, decoct to containing crude drug amount 0.30g/mL, 1 dose of every day, 1 dose is 100mL, and a point morning and evening takes for 2 times; SANJIN PIAN group is taken SANJIN PIAN, each 3 oral, every day 3 times.Respectively organize all taking 4 weeks as 1 course for the treatment of.Treat altogether 2 courses for the treatment of.Do not add Chinese patent medicine or antibiotics with other treatment Chronic Urinary Tract Infection.
1.4 observation of curative effect
1.4.1 observe short term effect and late relapse rate
With reference to " guideline of clinical investigations of new Chinese medicine treatment urinary system infection " relevant grade scale, be divided into recovery from illness, effective, effective, invalid.
1.4.2 tcm syndrome curative effect determinate standard
Adopt sxemiquantitative integration method to mark to symptom, degrees of symptoms is designated as respectively 0,1,2,3,4.Add up according to integration improvement situation.Total mark × 100% before therapeutic effect of syndrome rate=(the rear total mark of total mark-treatment before treatment)/treatment.Clinic control: therapeutic effect of syndrome rate >=95% after treatment; Effective: reach >=70-94% of therapeutic effect of syndrome rate after treatment; Effective: reach >=30-69% of therapeutic effect of syndrome rate after treatment; Invalid: therapeutic effect of syndrome rate < 30% after treatment.
1.4.3 Investigation on Quality of Life
Adopt SF-36 scale (medical outcome short-form 36 item health survey, SF-36).Quality of Life Scale is respectively investigated once including in before test and after test of cure 8 weeks.
1.5 statistical procedures
All data are processed with medical statistics software Spss13.0, measurement data data with mean scholar standard deviation (
soil s) represents, adopts t inspection; Enumeration data adopts X
2inspection.
2. result
This clinical research is included in altogether from Shanghai University of Chinese Medicine Affiliated Yueyang Integrated Traditional and Western Medicine Hospital's Urology Department outpatient service and ward medical female patient in year May in October, 2007 to 2008 and is amounted to case 120 examples, all selected, without rejecting and the case that comes off, respectively organize case and there is homogeneity (in table 1) at aspects such as age, the course of disease, menopause times.
The each group of table 1 case physical data (
± S)
Short term effect comparison after 2.1 each group patient treatments
The results are shown in Table 2.Chinese drug-treated group of the present invention, two fourth ERXIAN TANG groups respectively with the comparison of SANJIN PIAN group, the recent effective percentage for the treatment of Chronic Urinary Tract Infection is all obviously better than SANJIN PIAN group (P<0.05), Chinese drug-treated group of the present invention and two fourth ERXIAN TANG group comparisons, effective percentage difference no difference of science of statistics (P>0.05) in the recent period, but the recovery from illness case load of Chinese drug-treated group of the present invention is obviously more than two fourth ERXIAN TANG groups.
The each group of table 2 case treatment effective percentage comparison in the recent period after 8 weeks
Note: with the comparison of SANJIN PIAN group Emergent therapy effective percentage: * P<0.05.
2.2 each group case treatments are tcm syndrome curative effect and clinical symptoms integral contrast after 8 weeks
The results are shown in Table 3 and table 4.Each group all has good traditional Chinese medical science disease curative effect, can obviously improve clinical symptoms, but the SANJIN PIAN group (P<0.001) that is better than evident in efficacy of Chinese drug-treated group of the present invention and two fourth ERXIAN TANG groups, improves patient clinical symptom and is also significantly better than SANJIN PIAN group.Chinese drug-treated group of the present invention and two fourth ERXIAN TANG groups in tcm syndrome curative effect and improve aspect patient clinical symptom all without significant difference (P>0.05), but after Chinese drug-treated group of the present invention treatment, clinical symptoms integration will be lower than two fourth ERXIAN TANG groups.
The each group of table 3 case is treated the comparison of 8 weeks tcm syndrome curative effects
Note: with the comparison of SANJIN PIAN group: * P<0.001.
Clinical symptoms integral contrast before and after the treatment of the each group of table 4 case (
± S)
Note: relatively front with Chinese drug-treated group of the present invention or the treatment of two fourth ERXIAN TANG groups: △ P <0.001; Relatively front with the treatment of SANJIN PIAN group: ▲ P <0.05; Treat rear and the comparison of SANJIN PIAN group: * P <0.001.
SF-36 integral contrast before and after 2.3 each group case treatments
The results are shown in Table 5.With this group before treatment, Chinese drug-treated group of the present invention and two fourth ERXIAN TANG groups all can obviously be improved patient's quality of life (P<0.001).After treatment between group relatively: Chinese drug-treated group of the present invention and two fourth ERXIAN TANG groups respectively with the comparison of SANJIN PIAN group, treat eight weeks rear SF-36 integrations and significantly improves (P<0.05); Chinese drug-treated group of the present invention and two fourth ERXIAN TANG group comparisons, the SF-36 integration significantly higher (P<0.05) of Chinese drug-treated group of the present invention.
SF-36 integral contrast before and after the treatment of the each group of table 5 case
Late result comparison after 2.4 each group patient treatments
The results are shown in Table 6.Chinese drug-treated group of the present invention, two fourth ERXIAN TANG group interior relapse rates in June are all starkly lower than SANJIN PIAN group (P<0.05), and Chinese drug-treated group interior relapse rate in June of the present invention is starkly lower than two fourth ERXIAN TANG groups (P<0.05).The late result that shows Chinese drug-treated group preventing chronic urinary tract infection of the present invention and treatment Chronic Urinary Tract Infection is obviously better than two fourth ERXIAN TANG groups and SANJIN PIAN group.
Relapse rate comparison in the each group of table 6 case 6 months
2.5 untoward reaction and adverse events
Each group in therapeutic process all without obvious adverse reaction and adverse events.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and the supplementary protection scope of the present invention that also should be considered as.
Claims (6)
1. treat the Chinese medicine composition of urinary tract infection for one kind, it is characterized in that, it is to be made up of the crude drug of following weight portion: Rhizoma Anemarrhenae 10-15 part, Cortex Phellodendri 10-15 part, Herba Epimedii 10-15 part, Rhizoma Curculiginis 10-15 part, Radix Aconiti Lateralis Preparata 5-10 part, Semen Coicis 15-30 part, Herba Patriniae 15-30 part.
2. Chinese medicine composition according to claim 1, it is characterized in that, it is to be made up of the crude drug of following weight portion: Rhizoma Anemarrhenae 12-14 part, Cortex Phellodendri 12-14 part, Herba Epimedii 12-14 part, Rhizoma Curculiginis 12-14 part, Radix Aconiti Lateralis Preparata 7-9 part, Semen Coicis 20-25 part, Herba Patriniae 20-25 part.
3. Chinese medicine composition according to claim 2, is characterized in that, it is to be made up of the crude drug of following weight portion: 13 parts of the Rhizoma Anemarrhenaes, 13 parts of Cortex Phellodendris, 13 parts of Herba Epimedii, 13 parts of Rhizoma Curculiginises, 8 parts of Radix Aconiti Lateralis Preparatas, 22 parts of Semen Coicis, 22 parts of Herba Patriniae.
4. Chinese medicine composition according to claim 1, is characterized in that, the medicament of described Chinese medicine composition is decoction, capsule, granule, tablet or mixture.
5. the application of the arbitrary described Chinese medicine composition of claim 1-4 in the medicine of preparation treatment urinary tract infection.
6. the arbitrary described Chinese medicine composition of claim 1-4 is treated repeatedly the application in the medicine of urinary tract infection in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410243085.6A CN104001077A (en) | 2014-06-04 | 2014-06-04 | Traditional Chinese medicine composition for treating urinary tract infection and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410243085.6A CN104001077A (en) | 2014-06-04 | 2014-06-04 | Traditional Chinese medicine composition for treating urinary tract infection and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104001077A true CN104001077A (en) | 2014-08-27 |
Family
ID=51362165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410243085.6A Pending CN104001077A (en) | 2014-06-04 | 2014-06-04 | Traditional Chinese medicine composition for treating urinary tract infection and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104001077A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587301A (en) * | 2015-02-06 | 2015-05-06 | 青岛市市立医院 | Traditional Chinese medicinal composition for treating women's urinary tract infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085264A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine preparation for treating urinary tract infection |
| CN101953981A (en) * | 2009-07-21 | 2011-01-26 | 上海中医药大学附属岳阳中西医结合医院 | Chinese medicinal preparation for treating stranguria caused by overstrain |
| CN102283991A (en) * | 2011-07-27 | 2011-12-21 | 张秀兰 | Medicament for treating acute urinary system infection and preparation method thereof |
-
2014
- 2014-06-04 CN CN201410243085.6A patent/CN104001077A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085264A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine preparation for treating urinary tract infection |
| CN101953981A (en) * | 2009-07-21 | 2011-01-26 | 上海中医药大学附属岳阳中西医结合医院 | Chinese medicinal preparation for treating stranguria caused by overstrain |
| CN102283991A (en) * | 2011-07-27 | 2011-12-21 | 张秀兰 | Medicament for treating acute urinary system infection and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王国琛: "中老年复杂性尿路感染的中医治疗进展", 《江西中医学院学报》 * |
| 顾向晨等: "二丁二仙汤与三金片治疗再发性泌尿道感染的对照研究", 《中国中西医结合肾病杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587301A (en) * | 2015-02-06 | 2015-05-06 | 青岛市市立医院 | Traditional Chinese medicinal composition for treating women's urinary tract infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101884770B (en) | Chinese medicinal preparation for treating urolithiasis and preparation method thereof | |
| CN101700358B (en) | Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN101632750B (en) | Chinese medicinal composition for replenishing essence, filling marrow, boosting kidney and strengthening yang and preparation method thereof | |
| CN101961480A (en) | Traditional Chinese medicinal composition for treating hematochezia and preparation method thereof | |
| CN103933224A (en) | Traditional Chinese medicine composition for treating gout | |
| CN104435519B (en) | A kind of pharmaceutical composition for treating primary dysmenorrhea | |
| CN102423423A (en) | Traditional Chinese medicine for treating urinary tract infection | |
| CN103230566B (en) | Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof | |
| CN102895444B (en) | Traditional Chinese medicine composition for treating lithangiuria | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN104001077A (en) | Traditional Chinese medicine composition for treating urinary tract infection and application thereof | |
| CN102793870A (en) | Chinese herbal medicine for treating renal calculi | |
| CN102935155A (en) | Traditional Chinese medicine preparation for treating stroke and preparation process | |
| CN102743686B (en) | The scorching clearing capsule of a kind of basin | |
| CN101773620B (en) | Heat-clearing stranguria-treating drug | |
| CN101953981A (en) | Chinese medicinal preparation for treating stranguria caused by overstrain | |
| CN101433649A (en) | Composition for treating gall stone symptom | |
| CN101322771A (en) | Capsules for treating gynecology inflammation | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN100577199C (en) | Application of stomachic pill with cyperus and amomum | |
| CN1265818C (en) | Leech capsule | |
| CN100355436C (en) | Tibetan medicine for treating women's diseases, and its preparing method | |
| CN102836346B (en) | Traditional Chinese medicine for treating lumbar disc herniation | |
| CN102988945B (en) | Traditional Chinese medicine prescription for treating enteritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140827 |